nuclear cardiac imaging k.michalová

52
NUCLEAR CARDIAC IMAGING K.Michalová a nukleární medicíny a endokrinologie UK 2. LF a FN

Upload: delora

Post on 03-Feb-2016

96 views

Category:

Documents


1 download

DESCRIPTION

NUCLEAR CARDIAC IMAGING K.Michalová. Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol. Nuclear medicine methods in Cardiology are available for the evaluation of. 1. Myocardial Perfusion. 2. Ventricular Function. 3. Cardiac Metabolism and Myocardial Viability. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: NUCLEAR  CARDIAC         IMAGING K.Michalová

NUCLEAR CARDIAC IMAGING

K.Michalová

Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol

Page 2: NUCLEAR  CARDIAC         IMAGING K.Michalová

2. Ventricular Function

1. Myocardial Perfusion

3. Cardiac Metabolism and Myocardial Viability

4. Myocardial Innervation

Nuclear medicine methods in Cardiology are available for the evaluation of

5. Infarct Imaging

Kupka K .a kol: Nukleární medicína, 2007

Page 3: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

This test is designed to evaluate regional myocardial perfusion under rest and stress condition in order to define regional myocardial perfusion reserve.

Page 4: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

It involves the injecton of a radiolabelled substance which is extracted by the myocardium and accumulates in proportion to myocardial blood flow.Such radipharmaceuticals are injected under stress as well as resting conditions, and images are obtained to define the regional distribution of radioactivity within the myocardium.

Page 5: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

The main indication is the detection and localization

of myocardial ischaemia or scar.

Page 6: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

Myocardial ischaemia is defined as a perfusion defect present during stress but not resting conditions.Scar tissue is associated with a relative perfusion defect at rest as well as under stress.

Page 7: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

RADIOPHARMACEUTICALS

201Thallium

99mTc-Labeled Myocardial Perfusion Agents

99mTc-SESTAMIBI (MIBI, 2-methoxy-isobutyl-isonitril, Cardiolite, CardioSPECT…)

99mTc-Tetrofosmin (Myoview) 99mTc-Teboroxim

Page 8: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

201Thallium

- is an analog of potassium- it is actively transported into cardiac muscle via the sodium-potassium ATPase pump

Page 9: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

201Thallium

- is a cyclotron-produced radiopharmaceutical

- emits x-rays of energy 69- to 83 keV

- physical half-life is 74 h

Page 10: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

99mTc-SESTAMIBI x 201THALLIUM

ADVANTAGES :

- increased myocardial count density - lower radiation doses - no wash out of myocardium

Page 11: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

99mTc-SESTAMIBI

= is a lipophilic cationic Tc-99m complex - it enteres pasivelly into the cells - and binds at the intracells membranes, especially of mitochondrials - it does not wash out of the myocardium in 3-4 hours

Tc-99m-Labeled Myocardial Perfusion Agents

Page 12: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION SCINTIGRAPHY

99mTc-SESTAMIBI

99mTc - gamma rays of energy 140 keV - half life T1/2 = 6 hours

Page 13: NUCLEAR  CARDIAC         IMAGING K.Michalová
Page 14: NUCLEAR  CARDIAC         IMAGING K.Michalová

Exercise

Two-Day Patient Protocol

Delay Time (Intervals)

Injection - Imaging 15 min 60-90 min

Rest

Dose 700 MBq 700 MBq

Position Supine or prone Supine or prone

Page 15: NUCLEAR  CARDIAC         IMAGING K.Michalová

Exercise Stress

* is performed by cardiologist * graded stress is usually performed with bicycle ergometr * it is necessary to reach the gender and age predicted 85% maximal heart rate * suboptimal stress level reduce sensitivity of this procedure for detection of CAD * the radiopharmaceutical is injected 1-2 minut before end of exercise

Page 16: NUCLEAR  CARDIAC         IMAGING K.Michalová
Page 17: NUCLEAR  CARDIAC         IMAGING K.Michalová

Pharmacologic Stress

Patients who are unable to exercisefor non cardiac reasons - e.g.arthritis, amputation, neurologic diseases or cardiac reasons - with LBBBmay be stress farmacologically

Page 18: NUCLEAR  CARDIAC         IMAGING K.Michalová

Pharmacologic Stress

* vasodilators : adenosine dipyridamole* inotropic : dobutamine

Page 19: NUCLEAR  CARDIAC         IMAGING K.Michalová

Pharmacologic Stress using dipyridamole

* mechanism of action different from exercise* directly tests flow reserve* dipyridamol causes vasodilatation* normal vessel vasodilate, increasing flow five times* stenotic vessels are already maximally vasodilatated, cannot increase flow* results in heterogenity on scan * does not depend on induction of ischemia* Heart rate increases 13 beats per minute (20%)* Blood pressure decreases 6 mm Hg (2 ti 8%)* Contraindication: Asthma bronchiale

Page 20: NUCLEAR  CARDIAC         IMAGING K.Michalová

Pharmacologic Stress produced by dobutamine

* similar to exercise* indirectly tests flow reserve* increases myocardial oxygen consumption1) chronotropic effects2) ionotropic effects

Page 21: NUCLEAR  CARDIAC         IMAGING K.Michalová

Acquisition SPECT study Dual head gamma camera moves around the patient viewing the object in 180 degrees in 64 steps for 25 seconds

45 deg.RAO

135 deg. LPO

Page 22: NUCLEAR  CARDIAC         IMAGING K.Michalová
Page 23: NUCLEAR  CARDIAC         IMAGING K.Michalová

GATED SPECT study

• ECG is acquired at the time of the SPECT acquisition • for simultaneous assessment of perfusion and function of the left ventricle in one examination evaluation of regional wall motion ejection fraction systolic thickening of the walls

Page 24: NUCLEAR  CARDIAC         IMAGING K.Michalová

GATED SPECT study

We obtain myocardial perfusion images within one representative cardiac cycle : from end-diastole through end-systole to end-diastole of next cardiac cycle

Kamínek M. et al. : Atlas of Nuclear Cardiology, 2003

Page 25: NUCLEAR  CARDIAC         IMAGING K.Michalová

Initial Displayof selected study-Reconstruction

With ellipse we selectregion of the heartin anterior viewin left lateral view.

The selected data setsare processed.

We must alignment axes of heartfor creation of the vertical long and short axis tomograms

Summed image-added multiple projec-tion images

Page 26: NUCLEAR  CARDIAC         IMAGING K.Michalová

99m Tc-MIBI

slices in the short axis

slices in the long axis vertical

slices in the long axis horisontal

Page 27: NUCLEAR  CARDIAC         IMAGING K.Michalová
Page 28: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL ISCHEMIA

Can be identified by comparingthe results of exercise-injected studies and rest images .

As narrowing of coronary vessel approaches 70%lesion is hemodynamically significant during exercise.

Page 29: NUCLEAR  CARDIAC         IMAGING K.Michalová

99m-Tc-MIBI

Page 30: NUCLEAR  CARDIAC         IMAGING K.Michalová

Polar maps

Short axis slices are sequentially diplayed frombase to apex.

Conical myocardium is transformed into a disk.

Page 31: NUCLEAR  CARDIAC         IMAGING K.Michalová
Page 32: NUCLEAR  CARDIAC         IMAGING K.Michalová
Page 33: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION IMAGING

INTERPRETATION CRITERIA

1. NORMAL FINDINGS

2. REVERSIBILE DEFECT - lesion is seen at stress and improves on the rest - is usually due to ischemia

3. NONREVERSIBILE DEFECT - lesion at rest is usually associated with myocardial scar or with severe ischemia.

Page 34: NUCLEAR  CARDIAC         IMAGING K.Michalová

NORMAL FINDING

57 yo MALE

Page 35: NUCLEAR  CARDIAC         IMAGING K.Michalová

REVERSIBILE DEFECT

Page 36: NUCLEAR  CARDIAC         IMAGING K.Michalová

NONREVERSIBILE DEFECT

Page 37: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION IMAGING

Clinical Indications

Diagnosis of coronary artery disease - presence - location (coronary territory) -extent (number of vascular territories involved)Determine prognosis

Society of Nuclear Medicine Procedure Guideline for Myocardial Perfusion Imaging

Page 38: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION IMAGING

Clinical Indications

Determination of the significance of anatomic lesions detected by angiography

Page 39: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION IMAGING

Clinical Indications

Monitoring treatment effect after coronary revascularization

Page 40: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION IMAGING

Determine prognosis risk stratification

*Patients with normal perfusion imaging after adequate stress have a very low cardiac event rate independently of the presence or absence of angiographic CAD (yearly rate of myocardial infarction or death of less than 1%).

*A benign prognosis is asociated with a small fixed defectand a normal global left ventricle function.

Page 41: NUCLEAR  CARDIAC         IMAGING K.Michalová

57 yo MALE

Page 42: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL PERFUSION IMAGING

Determine prognosis risk stratification

* The risk of cardiac event can be suspected in all patients with the reversible perfusion defect.

* A higher risk can be expected in patients with a large perfusion defect, when more territories are affected, if the anterior wall is affected or if signs of postress dysfunction appear (transient ischemic dilation, deterioration of postress EF, increased uptake 201Tl in the lungs).

Page 43: NUCLEAR  CARDIAC         IMAGING K.Michalová
Page 44: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL VIABILITY

detection of myocardial viability has clinical importance for

- patients with chronic ischaemic left ventricular dysfunction and low left ventricle ejection fraction it is necessary to know, if defect of myocardial perfusion is

- ischemia vs. scar - predict improvement in function following revascularization

Page 45: NUCLEAR  CARDIAC         IMAGING K.Michalová

REQUIREMENTS FOR CELLULAR VIABILITY

-adequate myocardial blood flow-sarcolemmal metabolic integrity-preserved metabolic activity

Page 46: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL VIABILITY

The gold standard method

evaluation of myocardial glucose utilisation with fluorine-18 fluorodeoxyglucose (FDG)and positron emission tomography (PET)

Page 47: NUCLEAR  CARDIAC         IMAGING K.Michalová

MYOCARDIAL VIABILITY

Principle Under fasting conditions the normal myocardium primarily utilises free fatty acids. In ischaemic myocardium glucose becomes an important energy substrate, FDG uptake will be enhanced.

Page 48: NUCLEAR  CARDIAC         IMAGING K.Michalová

VIABLE MYOCARDIUMis characteristic in

NONREVERSIBILE PERFUSION DEFECT ( 99m-Tc MIBI) vs. PRESERVED MYOCARDIAL METABOLISM (18-FDG) = mismatch

Page 49: NUCLEAR  CARDIAC         IMAGING K.Michalová

99mTc MIBI

18FDG

non viable

match

viable

mismatch

- we can expect improvement in function following revascularization

Page 50: NUCLEAR  CARDIAC         IMAGING K.Michalová

99m-Tc-MIBI

Page 51: NUCLEAR  CARDIAC         IMAGING K.Michalová

SCARis characteristic in

NONREVERSIBILE PERFUSION DEFECT ( 99m-Tc MIBI) vs. NO PRESERVED MYOCARDIAL METABOLISM (18-FDG )

= match

Page 52: NUCLEAR  CARDIAC         IMAGING K.Michalová

99mTc MIBI

18FDG

nonviable

match

viable

mismatch

- we can´t expect improvement in function following revascularization